JP2008546714A5 - - Google Patents

Download PDF

Info

Publication number
JP2008546714A5
JP2008546714A5 JP2008517187A JP2008517187A JP2008546714A5 JP 2008546714 A5 JP2008546714 A5 JP 2008546714A5 JP 2008517187 A JP2008517187 A JP 2008517187A JP 2008517187 A JP2008517187 A JP 2008517187A JP 2008546714 A5 JP2008546714 A5 JP 2008546714A5
Authority
JP
Japan
Prior art keywords
disease
cancer
therapeutic agent
agent according
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008517187A
Other languages
English (en)
Japanese (ja)
Other versions
JP5368789B2 (ja
JP2008546714A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/023645 external-priority patent/WO2006138660A2/en
Publication of JP2008546714A publication Critical patent/JP2008546714A/ja
Publication of JP2008546714A5 publication Critical patent/JP2008546714A5/ja
Application granted granted Critical
Publication of JP5368789B2 publication Critical patent/JP5368789B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008517187A 2005-06-17 2006-06-15 スフィンゴシンキナーゼ阻害剤 Active JP5368789B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69156305P 2005-06-17 2005-06-17
US60/691,563 2005-06-17
PCT/US2006/023645 WO2006138660A2 (en) 2005-06-17 2006-06-15 Sphingosine kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2008546714A JP2008546714A (ja) 2008-12-25
JP2008546714A5 true JP2008546714A5 (enExample) 2009-07-30
JP5368789B2 JP5368789B2 (ja) 2013-12-18

Family

ID=37106302

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008517187A Active JP5368789B2 (ja) 2005-06-17 2006-06-15 スフィンゴシンキナーゼ阻害剤

Country Status (14)

Country Link
US (4) US7338961B2 (enExample)
EP (2) EP1904439B1 (enExample)
JP (1) JP5368789B2 (enExample)
KR (1) KR101386282B1 (enExample)
CN (1) CN101248041B (enExample)
AU (1) AU2006261327B2 (enExample)
BR (1) BRPI0611966B1 (enExample)
CA (1) CA2612338C (enExample)
ES (1) ES2528451T3 (enExample)
IL (1) IL187881A (enExample)
MX (1) MX2007015863A (enExample)
RU (1) RU2447060C2 (enExample)
WO (1) WO2006138660A2 (enExample)
ZA (1) ZA200800423B (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
EP1814854B1 (en) 2004-10-29 2015-02-25 MUSC Foundation For Research Development Cationic ceramides, and analogs thereof, and their use for preventing or treating cancer
CA2585645C (en) 2004-10-29 2014-10-21 Musc Foundation For Research Development Ceramides and apoptosis-signaling ligand
US8324237B2 (en) * 2005-05-20 2012-12-04 Smith Charles D Methods for the treatment and prevention of inflammatory diseases
ES2528451T3 (es) 2005-06-17 2015-02-10 Apogee Biothechnology Corporation Inhibidores de esfingosina cinasa
WO2007084391A2 (en) * 2006-01-18 2007-07-26 Amgen Inc. Thiazole compounds as protein kinase b ( pkb) inhibitors
US20100056600A1 (en) * 2007-03-28 2010-03-04 Soren Ebdrup 11beta-hsd1 active compounds
US7919504B2 (en) * 2007-07-17 2011-04-05 Amgen Inc. Thiadiazole modulators of PKB
EP2173728A2 (en) 2007-07-17 2010-04-14 Amgen Inc. Heterocyclic modulators of pkb
US8372888B2 (en) * 2008-04-29 2013-02-12 Enzo Therapeutics, Inc. Sphingosine kinase type 1 inhibitors, compositions and processes for using same
US8314151B2 (en) 2008-04-29 2012-11-20 Enzo Therapeutics, Inc. Sphingosine kinase type 1 inhibitors, and processes for using same
WO2010033701A2 (en) * 2008-09-19 2010-03-25 Genzyme Corporation Inhibitors of sphingosine kinase 1
EP2166094A1 (en) 2008-09-23 2010-03-24 Ecole Normale Superieure De Lyon Methods for prolonging the health benefits triggered by a dietary restriction using a sphingosine kinase inhibitor
CN102368905B (zh) 2008-11-06 2015-04-01 南卡罗来纳医科大学研究发展基金会 酸性神经酰胺酶的向溶酶体抑制剂
CA2754601C (en) 2009-03-12 2017-05-16 Apogee Biotechnology Corporation Sphingosine kinase inhibitor prodrugs
WO2010129954A1 (en) * 2009-05-08 2010-11-11 Apogee Biotechnology Corporation Treatment of ischemia-reperfusion injury
CA2808582A1 (en) 2009-08-14 2011-02-17 University Of Virginia Patent Foundation Imidamide sphingosine kinase inhibitors
MX2012006776A (es) * 2009-12-14 2012-10-05 Merck Patent Gmbh Inhibidores de la esfingosina quinasa.
JPWO2012121168A1 (ja) * 2011-03-04 2014-07-17 国立大学法人京都大学 キナーゼ阻害剤
RU2461544C1 (ru) * 2011-04-19 2012-09-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт вирусологии им. Д.И. Ивановского" Министерства здравоохранения и социального развития Российской Федерации Производные 1-(1-адамантил)этиламина и их противовирусная активность
US9688668B2 (en) 2012-02-08 2017-06-27 University Of Virginia Patent Foundation Long chain base sphingosine kinase inhibitors
RU2524216C1 (ru) * 2013-04-09 2014-07-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт вирусологии им. Д.И. Ивановского" Министерства здравоохранения Российской Федерации Пептидные производные 1-(1-адамантил)этиламина и их противовирусное действие
RU2529201C1 (ru) * 2013-06-18 2014-09-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный технический университет" (ВолгГТУ) Способ получения n-(2-гетероциклоалкил-1-илэтил)адамантан-2-аминов
US10100022B2 (en) 2014-10-01 2018-10-16 University Of Virginia Patent Foundation Sphingosine kinase inhibitors
CA2965258C (en) * 2014-10-24 2023-09-19 Redhill Biopharma Ltd. Therapy for inhibition of single-stranded rna virus replication
US11026918B2 (en) 2014-11-24 2021-06-08 The Board Of Trustees Of The University Of Illinois Method of preventing or treating a pulmonary disease or condition
CN107110853A (zh) * 2015-01-09 2017-08-29 阿通诺米斯公司 确定TNFα抑制药及其相应抗药抗体的量的通用测定法
CN104529859B (zh) * 2015-01-13 2016-08-17 佛山市赛维斯医药科技有限公司 含苯胺和二烯氟代金刚烷结构的化合物、其制备方法和用途
WO2017060771A2 (en) * 2015-10-06 2017-04-13 Redhill Biopharma Ltd. Combination therapies for treating cancer
RU2605698C1 (ru) * 2015-12-23 2016-12-27 Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный технический университет" (ВолгГТУ) Производные 2-(адамант-2-ил)этиламина, обладающие потенциальной противовирусной активностью
CA3011538A1 (en) * 2016-01-18 2017-07-27 Arisan Therapeutics Adamantane derivatives for the treatment of filovirus infection
JP6902040B2 (ja) 2016-01-28 2021-07-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 免疫チェックポイント阻害剤の効力を増強する方法
WO2017172989A1 (en) 2016-03-30 2017-10-05 Thorpe Steven Brandon Sphingosine kinase inhibitor amidoxime prodrugs
EP3468534A4 (en) * 2016-06-13 2020-02-05 Meharry Medical College MODULATION OF THE NITROGEN OXIDE SYNTHASE SIGNAL PATH FOR ORAL HEALTH
WO2018007327A1 (en) * 2016-07-08 2018-01-11 Atonomics A/S A universal assay for determining the quantity of therapeutic monoclonal antibodies and their corresponding anti-drug-antibodies in samples
CA3061201A1 (en) 2017-06-23 2018-12-27 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
US10660879B2 (en) 2017-06-23 2020-05-26 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
WO2019018185A1 (en) * 2017-07-15 2019-01-24 Arisan Therapeutics Inc. ENANTIOMERICALLY PURE ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONS
WO2019140254A1 (en) * 2018-01-12 2019-07-18 President And Fellows Of Harvard College Multicyclic compounds and use of same for treating tuberculosis
WO2019140265A1 (en) 2018-01-12 2019-07-18 President And Fellows Of Harvard College Trna synthetase inhibitors
EP3756012A1 (en) 2018-02-21 2020-12-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of sk1 as biomarker for predicting response to immunecheckpoint inhibitors
WO2019210866A1 (zh) * 2018-05-02 2019-11-07 中山大学 SphK2抑制剂作为骨髓造血系统损伤后修复或治疗骨髓造血功能障碍的药物的用途
RU2732297C2 (ru) * 2018-11-14 2020-09-15 Общество с ограниченной ответственностью "Гурус БиоФарм" Производные нестероидных противовоспалительных средств
CN111233887A (zh) * 2018-11-28 2020-06-05 武汉武药科技有限公司 一种盐酸多佐胺中间体的合成工艺
KR102887366B1 (ko) 2019-01-04 2025-11-14 (주)아모레퍼시픽 아다만탄 카르복실산 벤질 아마이드 유도체 화합물 및 그를 포함하는 피부 미백용 조성물
US20220062250A1 (en) * 2019-01-16 2022-03-03 Apogee Biotechnology Corporation Combination of a sk2 inhibitor and an inhibitor of a checkpoint pathway, uses and pharmaceutical compositions thereof
RU2697409C1 (ru) * 2019-04-30 2019-08-14 Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) 1-Адамантил-3-(((1R,4aS,10aR)-7-изопропил-1,4а-диметил-1,2,3,4,4а,9,10,10а-октагидрофенантрен-1-ил)метил)мочевина, проявляющая ингибирующее действие в отношении фермента тирозил-ДНК-фосфодиэстеразы 1 человека и увеличивающая активность темозоломида в отношении клеток глиобластомы
CN110330452A (zh) * 2019-06-12 2019-10-15 山东省医学科学院药物研究所（山东省抗衰老研究中心、山东省新技术制药研究所） 四氢吡咯烷类化合物或其药学上可接受的盐及其制备方法和应用
CN110483284B (zh) * 2019-08-26 2022-05-13 浙江工业大学 一种1-金刚烷甲酸-2-(取代苯甲酰氧基)乙酯类化合物及其合成方法和应用
CN117695284B (zh) 2020-03-10 2025-06-17 红山生物医药有限公司 冠状病毒感染的治疗
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
CN112336863A (zh) * 2020-11-26 2021-02-09 中山大学附属第八医院（深圳福田） S1p受体抑制剂在制备防治强直性脊柱炎产品中的应用
US11471448B2 (en) 2020-12-15 2022-10-18 Redhill Biopharma Ltd. Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia
CN116217468A (zh) * 2023-02-22 2023-06-06 天津民祥药业有限公司 一种奥帕尼布的新型合成方法
WO2026035293A1 (en) 2024-08-06 2026-02-12 Apogee Biotechnology Corporation Compositions and methods for the prevention and treatment of obesity and obesity-induced disease

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3352912A (en) * 1963-07-24 1967-11-14 Du Pont Adamantanes and tricyclo[4. 3. 1. 1 3.8] undecanes
US3663565A (en) * 1969-07-02 1972-05-16 Searle & Co Esters and amides of 3-phenyladamantane-1-carboxylic acid
US3657273A (en) * 1970-05-01 1972-04-18 Searle & Co Adamantane-1 3-dicarboxamides
US4053509A (en) * 1971-11-15 1977-10-11 Schering Corporation Substituted aryl and aralkyl amides
BE791392A (fr) * 1971-11-15 1973-05-14 Scherico Ltd Aryl- et aralcoylamides substitues
SU451691A1 (ru) * 1973-03-27 1974-11-30 Киевский Ордена Ленина Политехнический Институт Им.50-Летия Великой Октябрьской Социалистической Революции Способ получени -метилстеариламидов адамантанкарбоновых кислот
US4349552A (en) 1978-10-30 1982-09-14 Fujisawa Pharmaceutical Company, Ltd. 5-Fluorouracil derivatives, and their pharmaceutical compositions
JPS5671075A (en) * 1979-11-12 1981-06-13 Sumitomo Chem Co Ltd Novel imidazole derivative
EP0139504B1 (en) * 1983-10-07 1988-06-08 Exxon Research And Engineering Company Adamantylamine/long chain alkylamine catalysts and use in paraffin-olefin alkylation process
SU1367194A1 (ru) * 1984-03-16 1996-04-10 В.Ю. Ковтун Литиевая соль 1-адамантанкарбоновой кислоты, обладающая психостимулирующей активностью
SU1574586A1 (ru) * 1988-06-20 1990-06-30 Институт Биоорганической Химии Ан Усср Способ получени замещенных бромом адамантан-1-карбоновых кислот
ES2059602T3 (es) * 1989-04-14 1994-11-16 Merz & Co Gmbh & Co Uso de derivados de adamantano para la prevencion y tratamiento de isquemia cerebral.
JP2511573B2 (ja) * 1990-11-29 1996-06-26 川崎製鉄株式会社 １―エチルアダマンタンの製造方法
JPH04322743A (ja) * 1991-04-24 1992-11-12 Kawasaki Steel Corp アルキルアダマンタン類の製造用触媒およびこれを用いたアルキルアダマンタン類の製造方法
JPH04330947A (ja) * 1991-05-02 1992-11-18 Kawasaki Steel Corp １−ビニルアダマンタン製造用触媒およびこれを用いた１−ビニルアダマンタンの製造方法
EP0640072B1 (en) * 1992-05-15 2000-08-23 Btg International Limited Derivatives of pyridine as hydroxylase and lyase inhibitors
CN1158264C (zh) * 1997-11-21 2004-07-21 Nps药物有限公司 用于治疗中枢神经系统疾病的代谢性谷氨酸受体拮抗剂
CN100390178C (zh) 1999-11-12 2008-05-28 拜奥根Idec马萨诸塞公司 作为腺苷受体拮抗剂的多环烷基嘌呤
JP4271348B2 (ja) * 2000-06-16 2009-06-03 出光興産株式会社 １，３−アダマンタンジカルボン酸ジ−ｔｅｒｔ−ブチルの製造方法
RU2197467C2 (ru) * 2000-11-09 2003-01-27 Институт нефтехимии и катализа АН РБ и УНЦ РАН Способ получения 1-хлор-3-ацетил- и 1,3-дихлор-5-ацетиладамантанов
WO2003105840A2 (en) * 2002-06-17 2003-12-24 The Pennsylvania State Research Foundation Sphingosine kinase inhibitors
US20040116479A1 (en) * 2002-10-04 2004-06-17 Fortuna Haviv Method of inhibiting angiogenesis
ATE482747T1 (de) * 2003-04-11 2010-10-15 High Point Pharmaceuticals Llc Neue amide derivate und deren pharmazeutische verwendungen
JP2006522744A (ja) * 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ グルココルチコイド受容体アゴニスト療法に伴う副作用を最小化するための、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤およびグルココルチコイド受容体アゴニストを使用する併用療法
US20090093463A1 (en) * 2004-11-02 2009-04-09 Agouron Pharmaceuticals Inc. Novel compounds of substituted and unsubtituted adamantyl amides
GB0506133D0 (en) 2005-03-24 2005-05-04 Sterix Ltd Compound
US8324237B2 (en) * 2005-05-20 2012-12-04 Smith Charles D Methods for the treatment and prevention of inflammatory diseases
US20060270631A1 (en) * 2005-05-26 2006-11-30 Smith Charles D Methods for the treatment and prevention of angiogenic diseases
ES2528451T3 (es) * 2005-06-17 2015-02-10 Apogee Biothechnology Corporation Inhibidores de esfingosina cinasa
CA2754601C (en) * 2009-03-12 2017-05-16 Apogee Biotechnology Corporation Sphingosine kinase inhibitor prodrugs
WO2010129954A1 (en) * 2009-05-08 2010-11-11 Apogee Biotechnology Corporation Treatment of ischemia-reperfusion injury

Similar Documents

Publication Publication Date Title
JP2008546714A5 (enExample)
HRP20200974T1 (hr) Supstituirani indazoli, postupak za njihovu pripremu, farmaceutske formulacije koji ih sadrže i njihova upotreba za pripravu lijekova
JP2011525502A5 (enExample)
JP2016540749A5 (enExample)
JP2014512406A5 (enExample)
JP2013116921A5 (enExample)
CL2011001754A1 (es) Compuestos derivados de pirido pirazina, inhibidores de poli (adp-ribosa) polimerasa (parp); composicion y combinacion farmaceutica; y uso para el tratamiento de enfermedades o condiciones tales como cancer, enfermedades cardiovasculares, metabolicas, inflamatorias y neurodegenerativas.
JP2019532079A5 (enExample)
JP2013519684A5 (enExample)
JP2018524367A5 (enExample)
JP2014521625A5 (enExample)
HRP20170826T1 (hr) 5-fenil-[1,2,4]triazolo[1,5-a]piridin-2-il karboksamidi kao inhibitori jak
HRP20211002T1 (hr) 1,3-tiazol-2-il supstituirani benzamidi
HRP20161079T1 (hr) Selektivni inhibitori glikozidaze i njihove uporabe
JP2012509903A5 (enExample)
JP2017521469A5 (enExample)
JP2017519027A5 (enExample)
JP2017537948A5 (enExample)
JP2017509586A5 (enExample)
JP2005534715A5 (enExample)
NZ601924A (en) 4-phenyl pyridine analogues as protein kinase inhibitors
JP2010540562A5 (enExample)
JP2016507581A5 (enExample)
RU2010108470A (ru) Соединения фенилуксусной кислоты
EA200970852A1 (ru) Производные пиразоло[3,4-в]пиридина в качестве ингибиторов фосфодиэстеразы